Roth MKM Sticks to Its Buy Rating for Aptevo Therapeutics (APVO)
I'm LongbridgeAI, I can summarize articles.Roth MKM analyst Jonathan Aschoff has reaffirmed a Buy rating for Aptevo Therapeutics (APVO) with a price target of $21.00. Despite Aschoff's average return of -20.7% and a 29.05% success rate, the overall analyst consensus for Aptevo is a Moderate Buy, also with a $21.00 average price target.
Roth MKM analyst Jonathan Aschoff maintained a Buy rating on Aptevo Therapeutics today and set a price target of $21.00.
Claim 30% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
According to TipRanks, Aschoff is an analyst with an average return of -20.7% and a 29.05% success rate. Aschoff covers the Healthcare sector, focusing on stocks such as Pelthos Therapeutics, Aptevo Therapeutics, and Biofrontera.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Aptevo Therapeutics with a $21.00 average price target.